Pharmacokinetics, Dynamics and Metabolism, Medicine Design , Pfizer Worldwide R&D , Groton , Connecticut 06340 , United States.
Mol Pharm. 2018 Aug 6;15(8):3227-3235. doi: 10.1021/acs.molpharmaceut.8b00320. Epub 2018 Jun 25.
Organic anion transporter (OAT) 2 and OAT7 were recently shown to be involved in the hepatic uptake of drugs; however, there is limited understanding of the population variability in the expression of these transporters in liver. There is also a need to derive relative expression-based scaling factors (REFs) that can be used to bridge in vitro functional data to the in vivo drug disposition. To this end, we quantified OAT2 and OAT7 surrogate peptide abundance in a large number of human liver tissue samples ( n = 52), as well as several single-donor cryopreserved human hepatocyte lots ( n = 30) by a novel, validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. The average surrogate peptide expression of OAT2 and OAT7 in the liver samples was 1.52 ± 0.57 and 4.63 ± 1.58 fmol/μg membrane protein, respectively. While we noted statistically significant differences ( p < 0.05) in hepatocyte and liver tissue abundances for both OAT2 and OAT7, the differences were relatively small (1.8- and 1.5-fold difference in median values, respectively). Large interindividual variability was noted in the hepatic expression of OAT2 (16-fold in liver tissue and 23-fold in hepatocytes). OAT7, on the other hand, showed less interindividual variability (4-fold) in the livers, but high variability for the hepatocyte lots (27-fold). A significant positive correlation in OAT2 and OAT7 expression was observed, but expression levels were neither associated with age nor sex. In conclusion, our data suggest marked interindividual variability in the hepatic expression of OAT2/7, which may contribute to the pharmacokinetic variability of their substrates. Because both transporters were less abundant in hepatocytes than livers, a REF-based approach is recommended when scaling in vitro hepatocyte transport data to predict hepatic drug clearance and liver exposure of OAT2/7 substrates.
有机阴离子转运体 (OAT) 2 和 OAT7 最近被证明参与了药物在肝脏中的摄取;然而,对于这些转运体在肝脏中的表达的人群变异性,人们的了解有限。还需要推导出相对表达基础缩放因子 (REF),以便将体外功能数据与体内药物处置联系起来。为此,我们通过一种新的经过验证的液相色谱串联质谱 (LC-MS/MS) 方法,定量了大量人肝组织样本 (n=52) 和多个单供体冷冻保存的人肝细胞批次 (n=30) 中的 OAT2 和 OAT7 替代肽丰度。肝组织样本中 OAT2 和 OAT7 的替代肽平均表达分别为 1.52±0.57 和 4.63±1.58 fmol/μg 膜蛋白。虽然我们注意到 OAT2 和 OAT7 在肝细胞和肝组织中的丰度存在统计学上的显著差异 (p<0.05),但差异相对较小 (中位数分别相差 1.8 倍和 1.5 倍)。OAT2 在肝脏中的表达存在很大的个体间变异性 (肝组织中为 16 倍,肝细胞中为 23 倍)。另一方面,OAT7 在肝脏中的个体间变异性较小 (4 倍),但肝细胞批次的变异性较大 (27 倍)。观察到 OAT2 和 OAT7 表达之间存在显著的正相关,但表达水平与年龄或性别无关。总之,我们的数据表明 OAT2/7 在肝脏中的表达存在明显的个体间变异性,这可能导致其底物的药代动力学变异性。由于这两种转运体在肝细胞中的丰度均低于肝脏,因此建议在将体外肝细胞转运数据缩放以预测 OAT2/7 底物的肝清除率和肝脏暴露时,采用基于 REF 的方法。